Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.35 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14604365 | 1.00 | SLC15A2 (0.35) | SLC15A2MME | |
| SCHEMBL29891666 | 1.00 | SLC15A2 (0.35) | SLC15A2MME | |
| SCHEMBL14604358 | 1.00 | SLC15A2 (0.35) | SLC15A2MME | |
| SCHEMBL30822978 | 1.00 | SLC15A2 (0.35) | SLC15A2MME | |
| SCHEMBL30629016 | 1.00 | SLC15A2 (0.35) | SLC15A2MME | |
| SCHEMBL29630376 | 1.00 | SLC15A2 (0.35) | SLC15A2MME | |
| SCHEMBL30159237 | 1.00 | SLC15A2 (0.35) | SLC15A2MME | |
| SCHEMBL29519255 | 1.00 | SLC15A2 (0.35) | SLC15A2MME | |
| SCHEMBL30712894 | 1.00 | SLC15A2 (0.35) | SLC15A2MME | |
| SCHEMBL23598223 | 0.97 | MME (0.35) | MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240298636-A1 | ANTIMICROBIAL AGENTS AND FILMS MADE THEREFROM | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2024-09-12 | — | — | US | claimed |
| EP-4329492-A1 | ANTIMICROBIAL AGENTS AND FILMS MADE THEREFROM | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2024-03-06 | — | — | EP | claimed |
| CN-115884792-A | Targeted poly (beta-amino esters) | 艾夏卡法国有限公司 | 2023-03-31 | — | — | CN | claimed |
| WO-2022229951-A1 | ANTIMICROBIAL AGENTS AND FILMS MADE THEREFROM | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2022-11-03 | — | — | WO | claimed |
| CN-122070294-A | Stable vitreous material based on histidine, arginine and glutamic acid amino acids | 阵序补丁有限公司 | 2026-05-19 | — | — | CN | disclosed |
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | Biocrucible Limited (GB) | 2026-05-05 | — | — | US | disclosed |
| US-20260108614-A1 | IMMOBILIZED ENDOGLYCOSIDASE FUSION PROTEIN AND USE THEREOF | GENEQUANTUM HEALTHCARE SUZHOU CO LTD (CN) | 2026-04-23 | — | — | US | disclosed |
| EP-4688871-A1 | SITE-SPEICFIC ORTHOGONAL BIOCONJUGATE MODALITY AND APPLICATION THEREOF | Genequantum Healthcare (Suzhou) Co., Ltd. (CN) | 2026-02-11 | — | — | EP | disclosed |
| US-20250345411-A1 | VACCINATION IN NEWBORNS AND INFANTS | CureVac SE (DE) | 2025-11-13 | — | — | US | disclosed |
| US-20250345410-A1 | VACCINATION IN NEWBORNS AND INFANTS | CureVac SE (DE) | 2025-11-13 | — | — | US | disclosed |
| US-12390520-B2 | Vaccination in newborns and infants | Cure Vac SE (DE) | 2025-08-19 | — | — | US | disclosed |
| US-12377151-B2 | Immobilized endoglycosidase fusion protein and use thereof | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2025-08-05 | — | — | US | disclosed |
| US-11672856-B2 | Vaccination in newborns and infants | CureVac SE (DE) | 2023-06-13 | — | — | US | disclosed |
| WO-2023056460-A1 | WATER-SOLUBLE TETRAHYDROPYRENE BASED FLUORESCENT POLYMERS | BECKMAN COULTER, INC. (US) | 2023-04-06 | — | — | WO | disclosed |
| CN-115884792-A | Targeted poly (beta-amino esters) | 艾夏卡法国有限公司 | 2023-03-31 | — | — | CN | disclosed |
| WO-2022229951-A1 | ANTIMICROBIAL AGENTS AND FILMS MADE THEREFROM | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2022-11-03 | — | — | WO | disclosed |
| US-20220145378-A1 | BIOCHEMICAL REACTION METHODS AND REAGENTS COMPRISING INTRINSICALLY DISORDERED REGIONS | Biocrucible Limited (GB) | 2022-05-12 | — | — | US | disclosed |
| US-20220112547-A1 | BIOCHEMICAL REACTION METHODS AND REAGENTS COMPRISING INTRINSICALLY DISORDERED REGIONS | Biocrucible Limited (GB) | 2022-04-14 | — | — | US | disclosed |
| US-4591648-A | Histidine protection | NATIONAL RESEARCH DEVELOPMENT CORP. (GB) | 1986-05-27 | — | — | US | disclosed |
| EP-0061933-A2 | Histidine protection | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1982-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12377151-B2 | Immobilized endoglycosidase fusion protein and use thereof | ENGASE, FUT7, GALE | SLC15A2 2539/4885MME 175/4885 |
| US-20250345410-A1 | VACCINATION IN NEWBORNS AND INFANTS | HLA-DRB1, TLR3, TLR9 | SLC15A2 2828/4885MME 2664/4885 |
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | POLM, POLR1A, POLR1E | SLC15A2 4343/4885MME 1936/4885 |
| US-20260108614-A1 | IMMOBILIZED ENDOGLYCOSIDASE FUSION PROTEIN AND USE THEREOF | ENGASE, MGAT3, OGA | SLC15A2 2081/4885MME 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.